Literature DB >> 19957088

Dilated cardiomyopathy alters the expression patterns of CAR and other adenoviral receptors in human heart.

Raine Toivonen1, Mikko I Mäyränpää, Petri T Kovanen, Mikko Savontaus.   

Abstract

Gene therapy trials for heart failure have demonstrated the key role of efficient gene transfer in achieving therapeutic efficacy. An attractive approach to improve adenoviral gene transfer is to use alternative virus serotypes with modified tropism. We performed a detailed analysis of cardiac expression of receptors for several adenovirus serotypes with a focus on differential expression of CAR and CD46, as adenoviruses targeting these receptors have been used in various applications. Explanted hearts from patients with DCM and healthy donors were analyzed using Q-RT-PCR, western blot and immunohistochemistry. Q-RT-PCR and Western analyses revealed robust expression of all receptors except CD80 in normal hearts with lower expression levels in DCM. Immunohistochemical analyses demonstrated that CD46 expression was somewhat higher than CAR both in normal and DCM hearts with highest levels of expression in intramyocardial coronary vessels. Total CAR expression was upregulated in DCM. Triple staining on these vessels demonstrated that both CAR and CD46 were confined to the subendothelial layer in normal hearts. The situation was clearly different in DCM, where both CAR and CD46 were expressed by endothelial cells. The induction of expression of CAR and CD46 by endothelial cells in DCM suggests that viruses targeting these receptors could more easily gain entry to heart cells after intravascular administration. This finding thus has potential implications for the development of targeted gene therapy for heart failure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19957088     DOI: 10.1007/s00418-009-0666-1

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  40 in total

1.  Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor.

Authors:  K Asaoka; M Tada; Y Sawamura; J Ikeda; H Abe
Journal:  J Neurosurg       Date:  2000-06       Impact factor: 5.115

2.  CD46 is a cellular receptor for human herpesvirus 6.

Authors:  F Santoro; P E Kennedy; G Locatelli; M S Malnati; E A Berger; P Lusso
Journal:  Cell       Date:  1999-12-23       Impact factor: 41.582

3.  Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer.

Authors:  Kazumasa Matsumoto; Shahrokh F Shariat; Gustavo E Ayala; Katherine A Rauen; Seth P Lerner
Journal:  Urology       Date:  2005-08       Impact factor: 2.649

4.  Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy.

Authors:  M Noutsias; B Seeberg; H P Schultheiss; U Kühl
Journal:  Circulation       Date:  1999-04-27       Impact factor: 29.690

5.  Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors.

Authors:  J T Douglas; M Kim; L A Sumerel; D E Carey; D T Curiel
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

6.  Efficient infection of tumor endothelial cells by a capsid-modified adenovirus.

Authors:  K Shinozaki; E Suominen; F Carrick; B Sauter; V-M Kähäri; A Lieber; S L C Woo; M Savontaus
Journal:  Gene Ther       Date:  2006-01       Impact factor: 5.250

7.  The human CD46 molecule is a receptor for measles virus (Edmonston strain).

Authors:  R E Dörig; A Marcil; A Chopra; C D Richardson
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

8.  Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas.

Authors:  A G Zeimet; E Müller-Holzner; A Schuler; G Hartung; J Berger; M Hermann; M Widschwendter; J M Bergelson; C Marth
Journal:  Gene Ther       Date:  2002-08       Impact factor: 5.250

9.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

Review 10.  Current status of cardiovascular gene therapy.

Authors:  Tuomas T Rissanen; Seppo Ylä-Herttuala
Journal:  Mol Ther       Date:  2007-05-08       Impact factor: 11.454

View more
  4 in total

Review 1.  Histochemistry and cell biology: the annual review 2010.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2011-01-29       Impact factor: 4.304

Review 2.  A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy.

Authors:  Ming Yang; Chun Sheng Yang; WenWen Guo; JianQin Tang; Qian Huang; ShouXin Feng; AiJun Jiang; XiFeng Xu; Guan Jiang; Yan Qun Liu
Journal:  Cancer Biol Ther       Date:  2017-11-16       Impact factor: 4.742

3.  An attenuated coxsackievirus b3 vector: a potential tool for viral tracking study and gene delivery.

Authors:  Jun Zeng; Xiao xuan Chen; Jian ping Dai; Xiang feng Zhao; Gang Xin; Yun Su; Ge fei Wang; Rui Li; Yin xia Yan; Jing hua Su; Yu xue Deng; Kang sheng Li
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

4.  Intracardiac injection of a capsid-modified Ad5/35 results in decreased heart toxicity when compared to standard Ad5.

Authors:  Raine Toivonen; Juha Koskenvuo; Mari Merentie; Mirva Söderström; Seppo Ylä-Herttuala; Mikko Savontaus
Journal:  Virol J       Date:  2012-11-29       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.